<DOC>
	<DOCNO>NCT01372137</DOCNO>
	<brief_summary>This first clinical trial NOX-H94 . The purpose clinical trial identify safe efficacious treatment regimen clinical development NOX-H94 patient anemia chronic disease ( inflammation ) .</brief_summary>
	<brief_title>First-in-human Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics NOX-H94</brief_title>
	<detailed_description>NOX H94 pegylated Spiegelmer specifically bind human hepcidin , thereby antagonize role hemostasis , therefore indicate use anemia inflammation . Human hepcidin emerged central regulatory molecule systemic iron homeostasis . Hepcidin expression hepatocytes regulate multiple , particular opposing signal , include systemic iron availability , hepatic iron store , erythropoietic activity , hypoxia , inflammatory state . These different signal integrate transcriptionally . In chronic inflammation , occur rheumatoid arthritis , chronic kidney disease cancer , elevate hepcidin level measure may key factor lead anemia patient . NOX-H94 therefore indicate treatment patient anemia inflammation , characterize increase intracellular iron store , increase serum ferritin concentration reduce sensitivity treatment erythropoiesis stimulate agent ( ESAs ) , due limited availability serum iron . Antagonism hepcidin NOX-H94 therefore lead elevate level iron transferrin saturation peripheral blood could supply iron erythropoiesis thereby correct anemia .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion Criteria Male subject female subject nonchildbearing potential ( Groups A E ) , male subject ( group F H ) Age 1865 year Healthy determine medical history , physical examination , vital sign , 12lead electrocardiogram , clinical laboratory parameter Males willing use 2 mean contraceptive method least 2 month final examination 1 . Anemia predominantly cause factor chronic disease . 2 . Iron overload disturbance utilization iron . 3 . Intravenous iron treatment blood transfusion within 4 week prior screen visit . 4 . Erythropoietin treatment within 4 week prior screen visit . 5 . Intake Intravenous iron , Blood transfusion , Erythropoietin trial participation . 6 . Resting supine pulse rate &lt; 40 &gt; 100 beat / min . 7 . Resting supine blood pressure : Systolic blood pressure &lt; 90 &gt; 160 mmHg Diastolic blood pressure &lt; 40 &gt; 100 mmHg . 8 . History presence confirm orthostatic hypotension define . 9 . Positive test HIV type 1/2 antibody , HBs antigen , HBc antibody , HCV antibodies . 10 . Participation another clinical trial last 3 month start trial . 11 . Positive test drug abuse . 12 . Diseases condition know interfere absorption , distribution , metabolism excretion drug . 13 . Marked repolarization abnormality . 14 . Current bronchial asthma , childhood asthma resolve allow . 15 . Definite suspect history drug allergy hypersensitivity intolerance PEG 16 . Regular intake 14 unit alcohol per week woman 21 unit men . 17 . Not able abstain consumption : Caffeine contain beverage food ( tea , coffee , cola , chocolate , etc . ) Quinine contain beverage food ( bitter lemon , tonic water ) Grapefruit juice ( sweet sour ) Poppy seed contain beverage food 18 . Subjects donate blood , plasma platelet month prior screen 19 . History seizure risk 20 . Known suspect able comply trial protocol and/or clinical unit restriction . 21 . History presence clinically significant disease underlie disease . 22 . Surgery trauma significant blood loss within last 2 month administration study drug . 28 . History increase bleeding risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>NOX-H94</keyword>
	<keyword>Hepcidin</keyword>
	<keyword>Anemia</keyword>
	<keyword>Inflammation</keyword>
</DOC>